Search Results
Jul 30, 2025, 21:46 ET Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results. Mechanistic studies suggest that PD-1 therapy can restore the immune system's anti-tumor
More news about: Akeso, Inc.
Jul 30, 2025, 17:31 ET Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
as the market trends, market drivers, market barriers, and key chondrosarcoma companies, including Aadi Bioscience Inc., Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc., Atlanthera, Bayer AG, BioAtla Inc., BioMed, Valley Discoveries
More news about: DelveInsight Business Research, LLP
Jul 30, 2025, 09:15 ET Piramal Pharma Limited gibt Ergebnisse für das erste Quartal des Geschäftsjahres 2026 bekannt
Projekt zur Kapazitätserweiterung in Lexington (USA), das auf sterile injizierbare Arzneimittel spezialisiert ist. Dies sollte unserem integrierten ADC-Entwicklungs- und Herstellungsprogramm mittel- bis langfristig Auftrieb geben - Biotech-Finanzierung
More news about: Piramal Pharma Ltd
Jul 30, 2025, 08:00 ET CDI Labs Launches Pan-isotype Analysis of Serum Autoantibodies to Unlock Critical New Insights Into Humoral Immunity
autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream
More news about: CDI LABORATORIES, INC.
Jul 29, 2025, 18:53 ET Piramal Pharma Limited annuncia i risultati del primo trimestre dell'anno fiscale 2026
Uniti), specializzato in prodotti farmaceutici iniettabili sterili. Ciò dovrebbe dare impulso al nostro programma integrato di sviluppo e produzione di ADC nel medio e lungo termine - Finanziamenti per le biotecnologie - Recupero incompleto
More news about: Piramal Pharma Ltd
Jul 29, 2025, 17:31 ET Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
(olaparib) and TALZENNA (talazoparib) target defective DNA repair pathways. TRODELVY (sacituzumab govitecan), an antibody-drug conjugate (ADC) targeting TROP-2, is approved for relapsed or treatment-resistant metastatic TNBC. Although TECENTRIQ (atezolizumab) was withdrawn from the U.S.
More news about: DelveInsight Business Research, LLP
Jul 29, 2025, 06:43 ET Piramal Pharma Limited anuncia los resultados del primer trimestre del año fiscal 2026
(EE. UU.), empresa especializada en medicamentos inyectables estériles. Esto debería impulsar nuestro programa integrado de desarrollo y fabricación de ADC a medio y largo plazo. - Financiación en biotecnología: La recuperación incompleta e inconsistente
More news about: Piramal Pharma Ltd
Jul 28, 2025, 15:05 ET Piramal Pharma Limited Announces Results for Q1FY26
capacity expansion project at Lexington (US), which specializes in sterile injectable drug products. This should lend impetus to our integrated ADC development and manufacturing program over the medium to long term - Biotech Funding - Incomplete
More news about: Piramal Pharma Ltd
Jul 28, 2025, 15:01 ET Piramal Pharma Limited Announces Results for Q1FY26
capacity expansion project at Lexington (US), which specializes in sterile injectable drug products. This should lend impetus to our integrated ADC development and manufacturing program over the medium to long term - Biotech Funding - Incomplete
More news about: Piramal Pharma Ltd
Jul 28, 2025, 00:14 ET NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
cancer, among others. Ivonescimab has established a broad and strategic footprint across key cancer immunotherapy indications. As part of the company's "IO+ADC" 2.0 oncology strategy, ivonescimab is positioned as a cornerstone agent in immuno-oncology, being evaluated in combination with innovative therapies
More news about: Akeso, Inc.
Jul 27, 2025, 22:31 ET Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from
More news about: Antengene Corporation Limited
Jul 25, 2025, 10:00 ET FILM & TAPE EXPO 2025: Asia's Leading Functional Film and Adhesive Tape Show Returns to Shenzhen, Featuring Sustainability and Innovation.
Pre-Register now to secure your free pass to six shows: http://isclick.cn/ADC5E Online registration is free, onsite registration will be charged 15USD. Contact
More news about: RX Greater China
Jul 24, 2025, 21:00 ET Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
capabilities, including LeadsBody™ (a CD3 T-cell engager platform), X-body™ (a 4-1BB engager platform) and its linker-payload platform for ADC development. These platforms have demonstrated clinical proof-of-concept, particularly with bispecific antibody combinations. The LeadsBody™
More news about: Leads Biolabs
Jul 24, 2025, 17:31 ET B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight
indications such as breast cancer, non-small cell lung cancer, and others. Felmetatug vedotin is an investigational antibody-drug conjugate (ADC) built on the vedotin platform. It consists of a human monoclonal antibody targeting B7-H4, linked to the cytotoxic agent monomethyl auristatin E (MMAE)
More news about: DelveInsight Business Research, LLP
Jul 23, 2025, 09:24 ET Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jul 22, 2025, 17:31 ET ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight
June 2025, Merck presented the data from the Phase II/III waveLINE-003 study evaluating zilovertamab vedotin, an investigational ADC that targets ROR1, plus standard of care as a treatment for patients with relapsed or refractory DLBCL at the ASCO 2025 annual meeting.In
More news about: DelveInsight Business Research, LLP
Jul 22, 2025, 13:01 ET IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
China for IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). DLL3 is upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small
More news about: IDEAYA Biosciences, Inc.
Jul 22, 2025, 08:00 ET Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30,
More news about: Whitehawk Therapeutics, Inc.
Jul 21, 2025, 22:25 ET DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
as a next-generation HER3 ADC, to become a novel therapeutic option for a broad population of cancer patients." About DualityBio Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune
More news about: Duality Biotherapeutics
Jul 21, 2025, 08:33 ET GlycoNex to Participate in BIO Asia-Taiwan 2025
therapies and biosimilar development. GlycoNex will highlight progress with its development programs, including GNX1021, its novel antibody drug conjugate (ADC), SPD8, a denosumab biosimilar currently in Phase 3 clinical trials, and GlycoSH, an anti-glycan antibody bank suitable for early drug discovery.
More news about: GlycoNex, Inc.
Jul 17, 2025, 23:24 ET Bowtie獲C輪融資 Sun Life永明傾力支持
[5]Bowtie於《金融時報》「2025亞太區高增長企業」名單中 ，獲評為香港排名第一及亞太區排名第65位，金融時報網站：https://www.ft.com/content/98982fa6-e6cc-4e3d-85b6-fce9adc50252 關於BowtieBowtie
More news about: Bowtie Life Insurance Company Limited
Jul 16, 2025, 20:00 ET Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
IBI343（Anti CLDN18.2 ADC） IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell,
More news about: Innovent Biologics
Jul 16, 2025, 09:00 ET Acura and USA Bobsled/Skeleton Form Official Premier Technology and Automotive Partnership to Advance Performance Utilizing World-Class Honda Wind Tunnel in Ohio
vice president of Honda Development & Manufacturing of America, LLC (HDMA), with responsibility for the North American Auto Development Center (ADC). "In sports where sleds can reach speeds of over 90 miles per hour and the difference between first and last can be measured in fractions of a second,
More news about: Honda
Jul 09, 2025, 09:00 ET CDI Labs Canada Launches Hormone-focused PhIP-Seq Library for Highly Multiplexed Analysis of Serum Autoantibodies
autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream
More news about: CDI LABORATORIES, INC.
Jul 09, 2025, 08:30 ET Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
https://ibn.fm/tshxj). "Our top strategic objective for 2025 is the development of CX-2051, a wholly-owned, first-in-class PROBODY ADC being developed initially in advanced metastatic colorectal cancer (CRC)," said CytomX CEO and chair Sean McCarthy. "CX-2051
More news about: NetworkNewsWire